Targeting FOXM1 Reshapes Antitumor Immunity to Attenuate Small Cell Lung Cancer Progression

Scientists demonstrated that FOXM1 targeting small molecule inhibitors has the potential to be a novel therapeutic strategy to combat SCLC progression, including chemotherapeutic resistance and reshaping the anti-tumor immune response.